

PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/995,335
	Filing Date	November 27, 2001
	First Named Inventor	Antonio Verdini
	Art Unit	1653
	Examiner Name	David Lukton
Total Number of Pages in This Submission	Attorney Docket Number	29964/37956

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Reply to Communication Regarding Restriction Requirement <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MARSHALL, GERSTEIN & BORUN LLP Jeffrey S. Sharp - 31,879
Signature	
Date	December 2, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 2, 2004

Signature: (Jeffrey S. Sharp)



1653

[Handwritten signature]

PATENT
29964/37956

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

VERDINI et al.

Serial No.: 09/995,335

Filed: **November 27, 2001**

For: **PROCESS FOR FOLDING
CHEMICALKY SYNTHESIZED
POLYPEPTIDES**

Group Art Unit: 1653

Examiner: David Lukton

) I hereby certify that this paper and the
) documents referred to as enclosed
) therewith are being deposited with the
) United States Postal Service as first class
) mail, postage prepaid, in an envelope
) addressed to Commissioner for Patents,
) P.O. Box 1450, Alexandria, Virginia
) 22313-1450

December 2, 2004

[Handwritten signature]
Jeffrey S. Sharp

Registration No. 31,879

Attorney for Applicants

**RESPONSE TO COMMUNICATION REGARDING
RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This is in response to the Communication dated November 15, 2004 further to the
Restriction Requirement mailed June 18, 2004 in the above-identified application.

Applicants previously elected Group I but the Examiner has requested election of
four different species within that Group. Applicants hereby elect the following:

(a) a specific polypeptide to be refolded which is:

hu-I-309

See Example 4;

(b) a specific "chaotropic salt" which must be present during the folding which is:

guanidium chloride;

(c) a specific pH at which folding is to take place which is:

pH 8; and

(d) a specific reducing agent that is present in the folding buffer which is:

cysteine.

Each of claims 1 and 3-12 are readable upon these species.


Should the Examiner wish to discuss any issues of form or substance in order to expedite allowance of the pending application, he is invited to contact the undersigned attorney at the number indicated below.

The Commissioner is authorized to charge any fee deficiency required by the paper to Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300

By: _____


Jeffrey S. Sharp
Registration No.: 31,879
Attorney for Applicants

December 2, 2004